Financial Snapshot
| Metric | Q4 2025 Result | Year-over-Year Change |
| Revenue | $708.5 Million | Up 32.0% |
| GAAP Net Income | $135.1 Million | Up 15.5% |
| Diluted EPS | $4.67 | Down 27.2% |
| EBITDA | $160.2 Million | Up 20.0% |
| Net Book-to-Bill | 1.04x | Down (vs 1.2+ historical) |
Cancellations & Backlog Pressure
Cancellation Spike: CEO August Troendle revealed that cancellations in Q4 were “elevated” and represented the highest levels seen in over a year in both absolute and percentage terms.
Therapeutic Impact: The cancellations were concentrated heavily in the Metabolic therapeutic area. As pharmaceutical companies reprioritize their pipelines, some large-scale metabolic trials (likely related to GLP-1 or obesity drugs) were scrapped or scaled back.
Book-to-Bill Ratio: Consequently, the net book-to-bill ratio dropped to 1.04x. For a growth-focused CRO like Medpace, a ratio consistently above 1.20x is typically preferred to sustain high double-digit growth rates.
Management Commentary: “Only Time Will Tell”
During the conference call, management attempted to calm fears while remaining transparent about the volatility.
August Troendle, CEO said, “Cancellations were elevated again in Q4. This resulted in a lower than anticipated net book-to-bill ratio of 1.04. The good news is that with a backlog conversion rate of 23.6%, our book-to-bill rate does not need to be very high to generate growth.”
Troendle added that he sees “no reason to expect the higher level of cancellations to continue” but candidly admitted he “did not anticipate the spike in Q4,” concluding with a cautious, “Only time will tell.”
Full Year 2026 Guidance
Management issued guidance reflecting a moderation in growth compared to the surge seen in 2025.
Revenue: $2.755 billion to $2.855 billion (Implies 9%-13% growth).
EBITDA: $605 million to $635 million.
Diluted EPS: $16.68 to $17.50.
Strategic Highlights
Workforce Efficiency: Headcount grew only 5.7% YoY despite 32% revenue growth, highlighting significant productivity gains and margin protection.
Strong Cash Position: The company ended the year with $497 million in cash and no outstanding debt, providing ample dry powder for share repurchases or strategic investments.
Backlog Conversion: The conversion rate improved to 23.6%, helping to offset the slower booking pace.
Investor Outlook
Medpace remains a highly profitable, well-run machine with a pristine balance sheet. However, the Q4 results exposed a vulnerability: concentration risk. As the company grew its exposure to the hot metabolic space, it became susceptible to that sector’s volatility. The market is now waiting to see if the Q4 cancellation spike was a one-time blip or a signal of a broader slowdown in biotech R&D spending.